Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,125.56 34.04 1.10%
FTSE 100 6,572.45 30.84 0.47%
DAX 9,268.39 94.68 1.03%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Ironwood Pharmaceuticals Appoints Dr. Michael Hall as Senior Vice President of Clinical Development

  Ironwood Pharmaceuticals Appoints Dr. Michael Hall as Senior Vice President
  of Clinical Development

Business Wire

CAMBRIDGE, Mass. -- August 21, 2013

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that Michael
Hall, MB. BCh., has joined the company as senior vice president of clinical
development. Dr. Hall will lead Ironwood’s clinical research, clinical
development, clinical operations, biostatistics and pharmacovigilance teams.
In this role, he will oversee clinical trials investigating additional
appropriate populations for linaclotide, as well as Ironwood’s pipeline of
early development candidates.

Michael Hall, MB. BCh., senior vice president of clinical development,
Ironwood Pharmaceuticals Inc. ...

Michael Hall, MB. BCh., senior vice president of clinical development,
Ironwood Pharmaceuticals Inc. (Photo: Business Wire)

“Michael’s unique combination of drug development experience, deep scientific
knowledge, patient-oriented medical perspective, and proven leadership
capabilities will be of significant value in supporting our clinical
development activities,” said Mark Currie, Ph.D., senior vice president, chief
scientific officer, and president of research and development at Ironwood. “We
feel very fortunate to welcome Michael to our team.”

Prior to joining Ironwood, Dr. Hall served as chief medical officer and senior
vice president at Repligen Corp., where he oversaw the advancement of
late-stage programs through registration application and early-stage programs
into the clinic. He previously served as vice president of global clinical
affairs at Shire Human Genetic Therapies, where he led clinical research,
clinical operations and biostatistics, and he established a translational
medicine group supporting the early clinical and business development teams
that was instrumental in the in-licensing of multiple products. Dr. Hall
previously held medical affairs, pharmacovigilance and clinical positions at
Novartis Pharmaceuticals Corp. Prior to joining the pharmaceutical industry,
Dr. Hall worked at Hillbrow Hospital and Johannesburg General Hospital, both
in Johannesburg. He earned his MB. BCh. medical degree from the University of
Witwatersrand Medical School in Johannesburg.

“The discipline with which the team at Ironwood advances programs and the
degree to which they focus on science that addresses unmet needs of patients
were driving factors in my decision to join the company,” said Dr. Hall. “I
look forward to adding my clinical development and medical expertise to the
passionate and experienced team of pharmacologists and business leaders at

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is committed to the art and science of
making medicines, from discovery through commercialization. We’re focused on
three goals: transforming knowledge into medicines that make a difference for
patients, creating value that will inspire the continued support of our fellow
shareholders, and building a team that passionately pursues excellence. Our
first product, linaclotide, is approved in the United States and Europe. Our
pipeline priorities include exploring further opportunities for linaclotide,
leveraging our deep expertise in functional gastrointestinal disorders, and
advancing programs in other areas such as allergic conditions, cardiovascular
disease, central nervous system disorders and other conditions defined by
patient symptoms. Ironwood was founded in 1998 and is headquartered in
Cambridge, Mass. Connect with us at or on Twitter at to learn more about Ironwood. Information that
may be important to investors will be routinely posted in both these

Photos/Multimedia Gallery Available:



Ironwood Pharmaceuticals
Media Relations
Lisa Buffington, 617-374-5103
Vice President, Corporate Communications
Investor Relations
Meredith Kaya, 617-374-5082
Director, Investor Relations
Sponsored Links
Sponsored Links